Articles

Long-term mortality of patients with ischemic heart disease is independently predicted by diabetes…. Anna Norhammar, MD, PhD, of the cardiology unit in the department of medicine at Karolinska Institutet in Sweden, said during her presentation, “Diabetes is common among patients with heart failure that report ischemic heart disease and it’s …

“An interaction of genetic risk with physical activity on incident type 2 diabetes that appears to be driven principally through genetic risk to insulin resistance.”…  Yann C. Klimentidis, PhD, of the University of Arizona Mel and Enid Zuckerman College of Public Health in Tucson, and colleagues wrote, “It has been …

Besides sulfonylureas, GLP-1RA can also be a treatment option for HNF1A diabetic patients…. Maturity-onset diabetes of the young adults (MODY) is responsible for 1-2% of all cases of diabetes. HNF1A diabetes is caused by loss of B-cell functions. It is usually misclassified as type 1 diabetes due to common hyperglycemic …

No effect of tight glycemic control on mortality or major cardiovascular events in long-term follow-up of the ADVANCE trial….  The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE study) assessed the effects of routine blood-pressure lowering and strict glucose control in a broad cross …

Promising trial showed safe restoration of near-normoglycemia in type 1 diabetes…. Islet transplantation is a well-established therapeutic treatment for a subset of patients with difficult to control type 1 diabetes mellitus. Before the Edmonton Protocol, only 9% of the 267 islet transplant recipients since 1999 were insulin independent for more …

Changing the type of desks students use in schools could impact the health of our nation…. Obesity is a big concern and some adults are opting to use standing desks in favor of their standard office chairs as a way to avoid sitting during long hours at work, believing that …

Dulaglutide (Trulicity) is approved as a once-weekly injection for the treatment of type 2 diabetes…. Dulaglutide is a member of the glucagon-like peptide (GLP-1) receptor agonist class, along with liraglutide, exenatide, and albiglutide. The US Food and Drug Administration (FDA) has approved dulaglutide (Trulicity) as a once a week injection …

A large study in the UK looked at the long-term effects of GLP-1 and DPP-4 therapy on patients’ risk of congestive heart failure….

Using a GLP-1 agonist with insulin may be the most effective therapy combination for lowering HbA1c in type 2 diabetes patients…. Researchers performed a systematic review and pooled meta-analysis of randomized controlled trials published between January 1, 1950 and July 29, 2014. Out of the 2,905 studies that were identified, …

Low HDL increases the risk of heart disease but does it also increase the risk of cancer?…